<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_lamivudine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:22 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Lamivudine</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-25-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulation in Zambia: Oral liquid:</B> 50 mg/5 ml; <B>Tablet: </B>150 mg. <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> 300 mg/3TC 150 mg combination tab. <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> 300 mg/3TC 150 mg/<A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg combination tab </li>
<li>Co-formulations with 3TC: <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>+3TC (300&nbsp;mg+150&nbsp;mg); <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>+3TC+<A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> (300&nbsp;mg+150&nbsp;mg+200&nbsp;mg); <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>+3TC+<A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> (30&nbsp;mg+150&nbsp;mg+200&nbsp;mg). Dose: 1 tablet twice daily. </li>
<li>Active against <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>, but should be co-administered with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> in <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> co-infected patients to prevent emergence of 3TC resistance. </li>
<li>
<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> /3TC plus <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> no longer first-line ARV regimen in ARV-na&iuml;ve patients. <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> now preferred due to long-term efficacy, favorable mutation pathway, and lower incidence of anemia. </li>
<li>After <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> failure, <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/3TC plus <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> is recommended second line regimen. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm.D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals. </li>
<li>Treatment of hepatitis in HIV-<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> co-infected pts.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Epivir</I>
          </TD><TD valign="top">Lamivudine (3TC)</TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>150 mg, 300 mg</TD><TD>$6.10; $12.10</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>solution</TD><TD>10mg/mL (240mL)</TD><TD>$102.92</TD>
</TR>
        
<TR>
<TD valign="top"><I>Epivir HB </I>(for <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> infection)</TD><TD valign="top">Lamivudine (3TC)</TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>100 mg</TD><TD>$9.51</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral </TD><TD>solution</TD><TD>5 mg/mL (240 mL)</TD><TD>$114.23</TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Combivir</I>
          </TD><TD valign="top">Lamivudine (3TC)/<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">Zidovudine</A> (<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>)</TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>150 mg 3TC/300 mg <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A></TD><TD>$13.22</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD></TD><TD></TD><TD></TD><TD></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Trizivir</I>
          </TD><TD valign="top">Lamivudine (3TC)/<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">Zidovudine</A> (<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>)/<A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">Abacavir</A> (ABC) </TD><TD valign="top">GlaxoSmithKline</TD><TD>oral </TD><TD>tablet </TD><TD>ABC 300 mg + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> 300 mg + 3TC 150 mg </TD><TD>$20.90per tab </TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Epzicom</I>
          </TD><TD valign="top">Lamivudine (3TC)/<A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">Abacavir</A> (ABC) </TD><TD valign="top">GlaxoSmithKline </TD><TD>oral </TD><TD>tablet </TD><TD>ABC 600 mg + 3TC 300 mg </TD><TD>$28.59 per tab </TD>
</TR>
        
<TR>
<TD valign="top"><I>Kivexa </I>(brand name available in Europe)</TD><TD valign="top">ABC + 3TC</TD><TD valign="top">GlaxoSmithKline</TD><TD>oral</TD><TD>tablet</TD><TD>ABC 600 mg + 3TC 300 mg</TD><TD>variable</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 1-2 tabs qd<br>
<br>
<ul>
<li>As <I>Epivir:&nbsp;</I>3TC 300 mg PO qd or 150 mg PO bid. As <I>Combivir</I> or <I>Trizivir:</I> 1 tab PO bid. As <I>Epzicom</I>: 1 tab PO qd. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>300 mg qd or 150 mg PO bid <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>Cr Clearance 30-49 mL/min: 150 mg PO qd; Cr Clearance 15-29 mL/min: 150 mg x1 then 100 mg qd. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>150 mg x1 then 25-50 mg qd. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>25-50 mg qd (post HD). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>25-50 mg qd (limited data). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data consider 150 mg PO qd. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>One of the best tolerated NRTIs with side effect profile comparable to placebo in hepatitis trials.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Headache, nausea, <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A>, abdominal pain, and insomnia (association unclear; may be due to co-administered ARTs). </li>
<li>Fulminant hepatitis (in <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> co-infected pts if lamivudine is withdrawn or with the development lamivudine-resistant <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>) </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">LACTIC ACIDOSIS</A>: listed as NRTI class effect, but not clear that it is caused by 3TC. <I>In vi</I>tro, 3TC, along with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>, <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>, and <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>, are not clearly associated with mitochondrial toxicity.</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/pancreatitis91f4.html?contentInstanceId=432764">Pancreatitis</A> (reported in pediatric pts).</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>No pertinent drug interactions since it is not a substrate, inhibitor, or inducer of CYP450 isoforms.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>
          </B></TD><TD valign="top">3TC AUC decreased by 15%; Cmax decreased by 35%.</TD><TD valign="top">Not clinically significant. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>
          </B></TD><TD valign="top">No effect on 3TC AUC.</TD><TD valign="top">Not clinically significant. Use standard doses of both.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/cotrimoxazoleccc3.html?contentInstanceId=434631">Trimethoprim/ Sulfamethoxazole</A>
          </B></TD><TD valign="top">3TC AUC increased by 44%.</TD><TD valign="top">Not clinically significant. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Methadone</B></TD><TD valign="top">3TC: No reported interaction. Methadone: No change.</TD><TD valign="top">Not clinically significant. Use standard dose.</TD>
</TR>
</TABLE>
<a name="SPECTRUM"></a>
<h2 class="grayLineHeaderBar">SPECTRUM</h2>HIV and <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>
<br>
<br>
<a name="N109E6"></a>
<TABLE CELLPADDING="0" CELLSPACING="0"  BORDER="0"></TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>184V: selected by 3TC, resulting in high-level resistance to 3TC and <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>, slight decrease in susceptibility to <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> and <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>, and&nbsp;enhanced susceptibility to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, and <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>. </li>
<li>TAMs (41L, 210W, 215Y/F, 219Q/E, 67N, 70R): with multiple TAMs, resistance likely.</li>
<li>T69S: high-level resistance. </li>
<li>Q151M complex: high-level resistance.</li>
<li>K65R: intermediate resistance. </li>
<li>44D and 119I: increase 3TC resistance in combination with TAMs. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10A25"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Intracellular phosphorylation to active lamivudine triphosphate, which competitively inhibits HIV DNA polymerase.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                86%</li>
<li>Metabolism and Excretion: 
                Renal excretion accounts for 71%.</li>
<li>Protein Binding: 
                36%</li>
<li>Cmax, Cmin, and AUC: 
                Cmax = 3mcg/mL; Intracellular carbovir triphosphate 100 FM/million cells.</li>
<li>T1/2: 
                Serum: 5-7 hrs; Intracellular:12 hrs .</li>
<li>Distribution: 
                Widely distributed. Vd = 1.3 L/kg. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Usual dose.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>C-Negative carcinogenicity and teratogenicity studies in rodents. Placental passage ratio of 1.0 (newborn:mother). Well tolerated in pregnant pts.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No human data, breast milk excretion in animal studies. Breast feeding is not recommended in the U.S. in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: very well tolerated; active against <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>; convenient coformulations available; qd dosing with low pill burden (1 tab qd); longer-term safety data than <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>; increases susceptibility to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, and <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>; 3TC or <A class="headLines" target="_new" href="enfuvirtide5d38.html?contentInstanceId=443127">FTC</A> are essential components of all recommended initial regimens; coformulated with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> (<I>Combivir</I>), ABC (<I>Epzicom</I>), and <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> + ABC (<I>Trizivir</I>). </li>
<li>Cons: high level resistance with single point mutation (184V); risk of fulminant hepatitis if 3TC is withdrawn in co-infected pts; high rate of <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> resistance with prolonged therapy of <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>.</li>
</ul>
<a name="N10A98"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Castagna A, Danise A, Menzo S, et al.;
		Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).;        
		AIDS;
		2006; Vol. 
		20; pp. 
		795-803;
		<br>ISSN:
	        	0269-9370;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16549962&amp;dopt=abstract" target="_new">16549962</a>
<br>
<b>Comments:</b>This open-label pilot study determined if there is clinical or immunological benefit to continuing lamivudine in pts harbouring the M184V mutation. Pts were randomly assigned to monotherapy with lamivudine 300 mg once daily or the discontinuation of all ARV drugs (TI group). By wk 48, 20 of 29 pts in the TI group (69%) and 12 of 29 in the lamivudine group (41%) had discontinued the study because of immunological (CD4 &lt;350) or clinical failure, which was significantly delayed in the lamivudine group (P = 0.018). <br>
<br>
</li>
<li>Dienstag JL, Schiff ER, Wright TL, et al.;
		Lamivudine as initial treatment for chronic hepatitis B in the United States.;        
		N Engl J Med;
		1999; Vol. 
		341; pp. 
		1256-63;
		<br>ISSN:
	        	0028-4793;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=10528035&amp;dopt=abstract" target="_new">10528035</a>
<br>
<b>Comments:</b>Randomized, placebo-controlled trial in 34 centers in the U.S. with 66 untreated pts with <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> given 3TC 100 mg lamivudine/day for 52 wks. Statistically significant histologic improvement with lamivudine treatment in (52% vs. 23%), decreased levels of HBeAg(undetectable in 32% vs. 11%), and suppression of <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> DNA (44% vs. 16%). Rate of AEs same in both groups. Limitation of lamivudine monotherapy is the development of resistance, that occurred at rate of 15-20% yr. <br>
<br>
</li>
<li>Perry CM, Faulds D;
		Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.;        
		Drugs;
		1997; Vol. 
		53; pp. 
		657-80;
		<br>ISSN:
	        	0012-6667;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=9098665&amp;dopt=abstract" target="_new">9098665 </a>
<br>
<b>Comments:</b>Review article outlining therapeutic efficacy, pharmacokinetic properties, and antiviral activity. <br>
<br>
</li>
<li>Dragsted U, Fox Z, Mathiesen L, et al. ;
		Final wk 48 analysis of a phase 4, randomised, open-label, multi-center trial to evaluate safety and efficacy of continued lamivudine twice daily vs discontinuation of lamivudine in HIV-1-infected adults with virological failure on ongoing combination treatments containing lamivudine: the COLATE trial ;        
		12th CROI, San Francisco, California. 2004. Abstract 549. ;
		<br>
<b>Comments:</b>In vitro data suggest benefit of continuing 3TC after virological failure due to a decrease in viral fitness. This prospective randomized trial did not support this theory. At wk 48 the average decline in VL (AAUCMB) was comparable between the 2 groups (p=0.65). However, continuing 3TC despite M184V mutation may be beneficial for resistance reasons, especially in pts taking <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, or <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>. <br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="abacavir101c.html?contentInstanceId=432946&amp;siteId=429188">Abacavir</A>
</li>
<li>
<A class="headLines" target="_new" href="fosamprenavir1f69.html?contentInstanceId=257861&amp;siteId=429188">Fosamprenavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b101c.html?contentInstanceId=432946&amp;siteId=429188">Hepatitis B</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hepatotoxicity101c.html?contentInstanceId=432946&amp;siteId=429188">Hepatotoxicity</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapy101c.html?contentInstanceId=432946&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="lopinavir_ritonavir101c.html?contentInstanceId=432946&amp;siteId=429188">Lopinavir/Ritonavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_support101c.html?contentInstanceId=432946&amp;siteId=429188">Nutrition Care and Support</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/pregnancy_and_perinatal_transmission__zambia_specific_101c.html?contentInstanceId=432946&amp;siteId=429188">Pregnancy and perinatal transmission (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="stavudine101c.html?contentInstanceId=432946&amp;siteId=429188">Stavudine</A>
</li>
<li>
<A class="headLines" target="_new" href="tenofovir101c.html?contentInstanceId=432946&amp;siteId=429188">Tenofovir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/thrombocytopenia101c.html?contentInstanceId=432946&amp;siteId=429188">Thrombocytopenia</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/toxicity___side_effects__switching_therapy__zambia_spec101c.html?contentInstanceId=432946&amp;siteId=429188">Toxicity &amp; side effects: switching therapy (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/tuberculosis__active__zambia_specific_101c.html?contentInstanceId=432946&amp;siteId=429188">Tuberculosis, Active (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="zidovudine101c.html?contentInstanceId=432946&amp;siteId=429188">Zidovudine</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_lamivudine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:22 GMT -->
</html>
